Skip to main content

Table 2 Examples of ongoing sipuleucel-T combination studies

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Trial National clinical trial identifier Statusa
Concurrent vs. sequential sipuleucel-T and abiraterone NCT01487863 Randomized phase II, Reported in 2015 [44]
Sipuleucel-T +/- RT NCT01807065 Randomized Phase II, Recruiting, Expected completion date June 2017
Sipuleucel-T +/- pTVG-HP DNA booster vaccine NCT01706458 Randomized pilot study, Recruiting, Expected completion date December 2016
Sipuleucel-T + indoximod NCT01560923 Randomized phase II Recruiting, Expected completion date December 2016
Sipuleucel-T +/- ipilimumab NCT01804465 Randomized phase II, Recruiting, Expected completion date December 2017
Sipuleucel-T +/- radium - 223 NCT02463799 Randomized phase II, Recruiting, Expected completion date December 2018
  1. a As determined by ClinicalTrials.gov accessed October 31, 2016